GlassScriptPhysician profile
Roy Hood
NPI 1427046499
$14,737.95
in general payments reported to CMS, 2019-2025
47 companies · $2,253 in 2025
The $2,253 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,103 · 2020: $2,022 · 2021: $2,541 · 2022: $2,866 · 2023: $1,536 · 2024: $1,417 · 2025: $2,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,184 · Education: $21.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,183.76 |
| Education | $21.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,592.32 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,968.75 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,468.34 | 2019-2023 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $1,143.94 | 2019-2025 | |
| Janssen Biotech, INC. | $686.62 | 2019-2025 | Tremfya, Stelara, Simponi |
| Qol Medical, LLC | $579.91 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $564.39 | 2019-2025 | |
| Genzyme Corporation | $411.49 | 2022-2025 | |
| Braintree Laboratories, INC. | $381.71 | 2019-2024 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $347.09 | 2019-2023 | Linzess |
| Lilly USA, LLC | $264.95 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $254.80 | 2019-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $217.08 | 2021-2023 | |
| Celgene Corporation | $196.69 | 2021-2024 | Zeposia |
| Ferring Pharmaceuticals INC. | $188.31 | 2019-2020 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Hood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.